Introduction: Leishmaniasis – The Biology of a Parasite

  • A. Ponte-Sucre


One of the main problems of therapeutic tools for the treatment of parasitic diseases, including leishmaniasis, is that some field parasites are naturally resistant to classical drugs; additionally, current therapies may induce drug resistance. Treatment failure in leishmaniasis therefore has diverse causes. Some are related to drugs, such as pharmacokinetic properties, toxicity, use of suboptimal doses or high cost of treatment. Parasite-related grounds include chemo-resistance and tolerance. Finally, reasons attributable to the host may be related to the patient’s immune status and to reinfection. All these features are at least partially responsible for the disappointing persistence of leishmaniasis and its death and disability-adjusted life year toll worldwide. A better understanding of the disease itself and of drug resistance, its molecular basis, its consequences and possible avenues for better treatments may help improve this depressing picture. Experts in the field cover current knowledge and future trends of these and many other aspects of drug resistance in Leishmania in the present volume. This part offers a general introduction to the biology of Leishmania, a piece of knowledge fundamental to the various topics included in this book and for the comprehension of challenges we face currently for leishmaniasis.


Human Immunodeficiency Virus Visceral Leishmaniasis Cutaneous Leishmaniasis Insect Vector Direct Agglutination Test 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



The author is grateful for the financing support received from the Coordination for Research, Faculty of Medicine, UCV, and the Council for Scientific and Humanistic Research (CDCH), Universidad Central de Venezuela. Likewise she is grateful for the support conferred by the Alexander von Humboldt Foundation, Germany, to Alicia Ponte-Sucre.


  1. Akopyants NS et al (2009) Demonstration of genetic exchange during cyclical development of Leishmania in the sand fly vector. Science 324:265–268PubMedCrossRefGoogle Scholar
  2. Alten B et al (2003) Evaluation of protective efficacy of K-OTAB impregnated bednets for cutaneous leishmaniasis control in Southeast Anatolia, Turkey. J Vect Ecol 28:53–64Google Scholar
  3. Alvar J et al (2008) The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev 21:334–359PubMedCrossRefGoogle Scholar
  4. Ameen M (2010) Cutaneous and mucocutaneous leishmaniasis: emerging therapies and progress in disease management. Expert Opin Pharmacother 11:557–569PubMedCrossRefGoogle Scholar
  5. Bañuls AL, Hide M, Tibayrenc M (2002) Evolutionary genetics and molecular diagnosis of Leishmania species. Trans R Soc Trop Med Hyg 96:S9–S13PubMedCrossRefGoogle Scholar
  6. Bates PA, Rogers ME (2004) New insights into the developmental biology and transmission mechanisms of Leishmania. Curr Mol Med 4:601–609PubMedCrossRefGoogle Scholar
  7. Belkaid Y et al (1998) Development of a natural model of cutaneous leishmaniasis: powerful effects of vector saliva and saliva pre-exposure on the long term outcome of Leishmania major infection in the mouse ear dermis. J Exp Med 188:1941–1953PubMedCrossRefGoogle Scholar
  8. Berman J (2005) Clinical status of agents being developed for leishmaniasis. Expert Opin Investig Drugs 14:1337–1346PubMedCrossRefGoogle Scholar
  9. Bogdan C et al (1996) Invasion, control and persistence of Leishmania parasites. Curr Opin Inmunol 8:517–525CrossRefGoogle Scholar
  10. Buates S, Matlashewski G (1999) Treatment of experimental leishmaniasis with the inmunomodulators imiquimod. J Infect Dis 179:1485–1494PubMedCrossRefGoogle Scholar
  11. Castro-Sousa F et al (2001) Dissociation between vasodilation and Leishmania infection-enhancing effects of sand fly saliva and maxadilan. Mem Inst Oswaldo Cruz 96:997–999PubMedCrossRefGoogle Scholar
  12. Cattand P et al (2006) Tropical diseases lacking adequate control measures: dengue, leishmaniasis, and African trypanosomiasis. In: Jamison DT et al (eds) Disease control priorities in developing countries, 2nd edn. Oxford University Press, New York, pp 451–466. doi: 10.1596/978-0-821-36179-5/Chpt-23 Google Scholar
  13. Chang KP et al (2003) Leishmania model for microbial virulence: the relevance of parasite multiplication and pathoantigenicity. Acta Trop 85:375–390PubMedCrossRefGoogle Scholar
  14. Croft SL (2008) Kinetoplastida: new therapeutic strategies. Parasite 15:522–527PubMedGoogle Scholar
  15. Croft SL, Coombs GH (2003) Leishmaniasis: current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol 19:502–508PubMedCrossRefGoogle Scholar
  16. Croft SL et al (1987) The activity of alkyl phosphorylcholines and related derivatives against Leishmania donovani. Biochem Pharmacol 36:2633–2636PubMedCrossRefGoogle Scholar
  17. Croft SL, Sundar S, Fairlamb AH (2006) Drug resistance in leishmaniasis. Clin Microbiol Rev 19:111–126PubMedCrossRefGoogle Scholar
  18. Curtis CF (1992) Personal protection methods against vectors of disease. Rev Med Vet 80:543–553Google Scholar
  19. Davies CR et al (2000) The epidemiology and control of leishmaniasis in Andean countries. Cad Saude Publica 16:925–950PubMedCrossRefGoogle Scholar
  20. de Toledo JS et al (2010) Using genomic information to understand Leishmania biology. Open Parasitol J 4:156–166CrossRefGoogle Scholar
  21. Delgado O et al (1996) Follow up of human accidental infection by Leishmania braziliensis using conventional inmunologic techniques and polymerase chain reaction. Am J Trop Med Hyg 51:267–272Google Scholar
  22. Desjeux P (2004) Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol Infect Dis 27:305–318PubMedCrossRefGoogle Scholar
  23. Eibl H, Unger C (1990) Hexadecylphosphocholine: a new and selective antitumor drug. Cancer Treat Rev 17:233–242PubMedCrossRefGoogle Scholar
  24. Feliciangeli MD, Rabinovich J (1998) Abundance of Lutzomyia ovallesi but not Lu. gomezi (Diptera: Psychodidae) correlated with cutaneous leishmaniasis incidence in north-central Venezuela. Med Vet Entomol 12:121–131PubMedCrossRefGoogle Scholar
  25. Higgins CF (1992) ABC transporters: from microorganisms to man. Annu Rev Cell Biol 8:67–113PubMedCrossRefGoogle Scholar
  26. Kassi M et al (2008) Vector control in cutaneous leishmaniasis of the old world: a review of literature. Dermatol Online J 14:1PubMedGoogle Scholar
  27. Kedzierski L et al (2009) Leishmaniasis: current treatment and prospects for new drugs and vaccines. Curr Med Chem 16:599–614PubMedCrossRefGoogle Scholar
  28. Lerner EA et al (1991) Isolation of maxadilan, a potent vasodilatadory peptide from the salivary glands of the sandfly Lutzomyia losgipalpis. J Biol Chem 261:11234–11236Google Scholar
  29. Lessa MM et al (2007) Mucosal leishmaniasis: epidemiological and clinical aspects. Braz J Otorhinolaryngol 73:843–847PubMedGoogle Scholar
  30. Loiseau PM, Cojean S, Schrével J (2011) Sitamaquine as a putative antileishmanial drug candidate: from the mechanism of action to the risk of drug resistance. Parasite 18:115–119PubMedGoogle Scholar
  31. Malafaia G (2009) Protein-energy malnutrition as a risk factor for visceral leishmaniasis: a review. Parasite Immunol 31:587–596PubMedCrossRefGoogle Scholar
  32. Melby P (2002) Recent developments in leishmaniasis. Curr Opin Infect Dis 15:485–490PubMedCrossRefGoogle Scholar
  33. Molineux W, Killick-Kendrick R (1987) Leishmaniasis in biology and medicine. In: Peters W, Killick-Kendrick R (eds) Leishmaniasis in biology and medicine. Academic, New York, pp 794–845Google Scholar
  34. Murray H (2001) Clinical and experimental advances in treatment of visceral leishmaniasis. Antimicrob Agents Chemother 45:2185–2197PubMedCrossRefGoogle Scholar
  35. Natera S et al (2007) Proficiency of drug-resistant parasites. Int J Antimicrob Agents 29:637–642PubMedCrossRefGoogle Scholar
  36. Palumbo E (2009) Current treatment for cutaneous leishmaniasis: a review. Am J Ther 16:178–182PubMedCrossRefGoogle Scholar
  37. Peacock CS et al (2007) Comparative genomic analysis of three Leishmania species that cause diverse human disease. Nat Genet 39:839–847PubMedCrossRefGoogle Scholar
  38. Peters NC et al (2008) In vivo imaging reveals an essential role for neutrophils in leishmaniasis transmitted by sand flies. Science 321:970–974PubMedCrossRefGoogle Scholar
  39. Ponte-Sucre A (2003) Physiological consequences of drug resistance in Leishmania and their relevance for chemotherapy. Kinetoplastid Biol Dis 2:14PubMedCrossRefGoogle Scholar
  40. Quinnell RJ, Courtenay O (2009) Transmission, reservoir hosts and control of zoonotic visceral leishmaniasis. Parasitology 136:1915–1934PubMedCrossRefGoogle Scholar
  41. Ready PD (2010) Leishmaniasis emergence in Europe. Euro Surveill 15:19505PubMedGoogle Scholar
  42. Ridley D (1999) The pathogenesis of cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 73:156–160Google Scholar
  43. Ritter U, Frischknecht F, van Zandbergen G (2009) Are neutrophils important host cells for Leishmania parasites? Trends Parasitol 25:505–510PubMedCrossRefGoogle Scholar
  44. Romero GA, Boelaert M (2010) Control of visceral leishmaniasis in Latin America a systematic review. PLoS Negl Trop Dis 4:e584PubMedCrossRefGoogle Scholar
  45. Rotureau B (2006) Are New World leishmaniases becoming anthroponoses? Med Hypotheses 67:1235–1241PubMedCrossRefGoogle Scholar
  46. Rougeron V et al (2009) Extreme inbreeding in Leishmania braziliensis. Proc Natl Acad Sci U S A 106:10224–10229PubMedCrossRefGoogle Scholar
  47. Salotra P, Singh R (2006) Challenges in the diagnosis of post kala-azar dermal leishmaniasis. Indian J Med Res 123:295–310PubMedGoogle Scholar
  48. Schönian G et al (2008) Leishmaniases in the Mediterranean in the era of molecular epidemiology. Trends Parasitol 24:135–142PubMedCrossRefGoogle Scholar
  49. Sharma U, Singh S (2009) Immunobiology of leishmaniasis. Indian J Exp Biol 47:412–423PubMedGoogle Scholar
  50. Smith DF, Peacock CS, Cruz AK (2007) Comparative genomics: from genotype to disease phenotype in the leishmaniases. Int J Parasitol 37:1173–1186PubMedCrossRefGoogle Scholar
  51. Soto J, Berman J (2006) Treatment of New World cutaneous leishmaniasis with miltefosine. Trans R Soc Trop Med Hyg 100:S34–S40PubMedCrossRefGoogle Scholar
  52. Sundar S et al (2005) Detection of Leishmanial antigen in the urine of patients with visceral leishmaniasis by a latex agglutination test. Am J Trop Med Hyg 73:269–271PubMedGoogle Scholar
  53. t’Kindt R et al (2010) Metabolomics to unveil and understand phenotypic diversity between pathogen populations. PLoS Negl Trop Dis 4:e904PubMedCrossRefGoogle Scholar
  54. Tavares CA, Fernandes AP, Melo MN (2003) Molecular diagnosis of leishmaniasis. Expert Rev Mol Diagn 3:657–667PubMedCrossRefGoogle Scholar
  55. Thakur CP (2006) Leishmaniasis research – the challenges ahead. Indian J Med Res 123:193–194PubMedGoogle Scholar
  56. WHO (2010) Leishmaniasis, back ground information (
  57. Zerpa O et al (2007) Diffuse cutaneous leishmaniasis responds to miltefosine but then relapses. Br J Dermatol 156:1328–1335PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 2013

Authors and Affiliations

  1. 1.Laboratorio de Fisiología Molecular, Instituto de Medicina Experimental, Escuela Luis RazettiUniversidad Central de Venezuela, Ciudad UniversitariaLos ChaguaramosVenezuela

Personalised recommendations